Likewise, HER2 over-expression in the breast cancer as well as gastric cancer anticipates for stimulus to anti-Her2 drugs such as trastuzumab [62,63,64,65,66,67], and over-expression of estrogen receptor anticipates for stimulus to anti-endocrine therapy or treatment such as tamoxifen in breast cancer [68,69]. Here, ERBB2 is linked to breast carcinoma.